Products
Latest News
FAQ
|
Search
Search
Filters
Clear All
Study Phase
Early Phase 1
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
Phase 4
Not Applicable
Recruitment Status
Recruiting
Not yet recruiting
Active, not recruiting
Completed
Suspended
Terminated
Withdrawn
Study Type
Interventional
Observational
Expanded Access
Others
Eligibility Sex
All
Female
Male
Healthy Volunteers
All
Include
Exclude
Found
1
clinical trials
|
View Analysis
Sort by:
Newest First
The Efficacy and Safety of Tislelizumab Combined With Anlotinib and S1 Plus Oxaliplatin as Neoadjuvant Therapy for the Locally Advanced Adenocarcinoma of Esophagogastric Junction
Phase 2
Not yet recruiting
Conditions
Immunotherapy Gastroesophageal Junction
Interventions
Drug: Tislelizumab
Drug: Anlotinib
Drug: Oxaliplatin
Drug: Tegafur
Subscribe
First Posted Date
2024-05-02
Last Posted Date
2024-05-07
Lead Sponsor
Fujian Cancer Hospital
Target Recruit Count
28
Registration Number
NCT06396585
Locations
🇨🇳
Fujian cancer hospital, Fuzhou, Fujian, China
Subscribe
Prev
1
Next
© Copyright 2025. All Rights Reserved by MedPath
Home
Terms & Conditions
Privacy Policy